New Insights. New Hope.

HemoShear Therapeutics is a drug discovery company. We apply our deep understanding of complex diseases to discover new treatments for patients with rare metabolic disorders. We also partner with biopharma companies to accelerate their drug discovery and development programs in liver diseases, gout, cancer and other conditions. We are implementing a new vision for how advanced biological systems can yield new insights that improve health and quality of life for patients in need.

The HemoShear Advantage

The biopharmaceutical industry’s drug development success is impeded by a lack of physiological models that reflect the complexity of disease. HemoShear’s proprietary REVEAL-Tx™ platform combines biological and computational models of human disease to accelerate discovery of novel targets and successful new drug treatments.

Advanced Disease ModelsAdvanced Disease Models Computational InsightComputational Insight Accelerated DiscoveryAccelerated Discovery
Advanced Disease Models

We have developed transformational physiological models of human diseases by applying principles of physiological blood flow to tissue from patients to recapitulate their disease. Our models enable valuable insights into complex disease pathways and drug responses in a more meaningful human-relevant context.

Computational Insight

We leverage powerful computational science to extract signaling pathways from our disease models and identify novel therapeutic targets for treating diseases. We then assess our computational target hypotheses in our biological disease models.

Accelerated Discovery

The REVEAL-Tx™ platform enables HemoShear and our partners to gain unprecedented insight into the underlying mechanisms of disease, rapidly translate those discoveries into drug candidates, and reduce risk of failure by reliably assessing which drug candidates will be safer and more effectively treat patients.

Discovering Treatments for Rare Diseases

HemoShear is discovering novel drug treatments to extend and improve the quality of life of patients with rare metabolic diseases. These genetic disorders are caused by deficiencies of certain enzymes required to metabolize proteins that leads to the rapid buildup of life-threatening toxins. Using our transformational models of these devastating diseases, our scientists are identifying and validating promising approaches to combat several inborn errors of metabolism.

Read More  »

Transformative Partnerships

We leverage our REVEAL-Tx™ disease modeling platform for our proprietary drug discovery programs and for exclusive collaborations with partners who want to accelerate their drug discovery initiatives. 

Takeda Pharmaceutical Company
Fibrotic Liver Diseases
Horizon Therapeutics
Gout
Carnot BioSciences
Inborn Errors of Metabolism

Featured News

April 17th, 2019

Q&A on HemoShear’s 3D model of the tumor microenvironment

Read more at DDN News
March 20th, 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
March 6th, 2019

HemoShear Therapeutics Physiological Human Tumor Model Published in Lab on a Chip Journal

Read More »
January 3rd, 2019

Horizon Pharma Plc and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration in Gout

Read More »
December 4th, 2018

Carnot Biosciences, A Spin Off Of Smartzyme Biopharma, And Hemoshear Therapeutics Partner To Develope Protein-Based Therapeutics For Rare Metabolic Diseases

Read More »
November 9th, 2018

Shear Insights: HemoShear Identifies Novel Targets for Treating Liver Diseases

Read More »
All News »

Contact

info@hemoshear.com

501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902